RenovoRx, Inc.
No enriched coverage for $RNXT in the last 7 days.
No SEC Form 4 filings for $RNXT in the last 30 days.
See all $RNXT insider activity →RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.
Tenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
Recent RNXT coverage spans market movers, technology and corporate actions.
Positive trial results could boost valuation and near‑term buying pressure.
Positive Phase 3 data may boost near‑term demand and support further upside.
Positive trial data may drive further upside.
Modest pre‑market gain reflects mild bullishness.
Positive trial sub‑study data may improve perception of RenovoRx's TAMP platform and support future valuation, but immediate stock fell 2.1% on heavy selling.
AlphAI scores every news story that mentions RNXT with an AI model for sentiment and relevance, and aggregates insider trades from RenovoRx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
3 min readSeveral biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.
2 min readTenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
3 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readRenovoRx (RNXT) reported peer-reviewed data showing ~51% local drug extraction at the tumor site in a sub-study of its Phase III TIGeR-PaC trial. The study compared intra-arterial gemcitabine (IAG) with intravenous gemcitabine (IVG) in 16 patients with locally advanced pancreatic cancer. IAG resulted in lower systemic exposure and a significant correlation between dFdU levels and CA 19-9 tumor marker reduction. The company reported $1.1M in 2025 sales and $909,000 in Q2 2026 revenue. The stock d
3 min readRenovoRx (RNXT) regained Nasdaq compliance after its stock maintained a $1 minimum bid for 10 days. The company reported Q2 revenue of $909,000, expanded its cancer center customer base, and completed enrollment in its Phase 3 TIGeR-PaC trial. RNXT stock closed at $1.32, down 3.77% in pre-market trading.
1 min readRenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.
6 min readRenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.
6 min readRenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.
2 min readRenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN (as amended on April 16, 2026) Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “ Plan ”). The purposes of the Plan are to (i)
2 min read
